Tefirma

Tefirma Therapeutics is a biotechnology company focused on developing next-generation regulatory T cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Founded by experts in immunology from the University of California, San Francisco, the company leverages a proprietary platform to engineer Tregs that can specifically target and suppress aberrant immune responses in tissues like the skin. Their lead programs aim to provide durable, localized immune tolerance without the systemic side effects of traditional immunosuppressants. By utilizing tissue-specific engineering, Tefirma seeks to revolutionize the management of chronic immune-mediated conditions.